FEDERALhearing transcript

Congressional Hearing on FDA Approval and Antitrust Issues

Original title: ANTITRUST CONCERNS AND THE FDA APPROVAL PROCESS

January 1, 2018

FDA antitrust drug approval healthcare competition pharmaceutical regulation

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

The Frame

What this does

The hearing explores whether current FDA drug approval procedures inadvertently create barriers to competition that could affect the cost and availability of prescription medications for consumers.

Who is mentioned in the record

Potentially affected actors named in the source documents. Mention is not a position.

Pharmaceutical companies

These companies are subject to FDA approval processes and antitrust regulations discussed in the hearing.

Consumers

Changes in drug approval and competition policies may influence the cost and availability of prescription medications.

What changed

Last recorded activity January 1, 2018.

What's next

Next step not available in the current record.

Summary

This document is the official record of a 2017 House Judiciary Subcommittee hearing examining the intersection of FDA drug approval processes and laws. Lawmakers and expert witnesses discussed how regulatory pathways may impact market competition for pharmaceutical products.

Key Facts

The hearing took place on July 27, 2017, in the Rayburn House Office Building.
The session was held by the Subcommittee on Regulatory Reform, Commercial and Antitrust Law.
Witnesses included representatives from the FDA, the Federal Trade Commission, and various academic and policy experts.
The primary focus was the relationship between FDA regulatory approval processes and antitrust enforcement in the pharmaceutical industry.
The hearing record includes submitted statements and articles from committee members regarding drug competition.

Frequently Asked Questions

What was the purpose of this hearing?

To examine how es interact with laws and whether these processes affect competition in the pharmaceutical market.

Who testified at this hearing?

Witnesses included the FDA Commissioner, an official from the Federal Trade Commission, and several professors and legal experts specializing in law and medicine.

Why It Matters

The hearing explores whether current FDA drug approval procedures inadvertently create barriers to competition that could affect the cost and availability of prescription medications for consumers.

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Discoveries

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

policy shift80% confidence

Inter-agency focus on drug competition

The hearing highlights a coordinated effort between the Judiciary Committee, the FDA, and the FTC to address market competition in the pharmaceutical sector.

Food & Drug Administration Federal Trade Commission

Connected Entities

personScott Gottlieb“Commissioner of the Food & Drug Administration”Map →

organizationHouse Committee on the Judiciary“Congressional committee overseeing the hearing”Map →

personMarkus H. Meier“Acting Director, Bureau of Competition, Federal Trade Commission”Map →

personTom Marino“Chairman of the Subcommittee on Regulatory Reform, Commercial and Antitrust Law”Map →

Sources

Open source document

www.govinfo.gov

Analysis Score

0–100

Significance65
How much this matters to a regular citizen
Controversy40
Intensity of disagreement among stakeholders
Entertainment10
Compellingness for a non-policy-wonk reader
Buzz15
Current news / social attention level

Publisher tools